Evidence map›Paper›PMID 35784479›Full record

ArticleFrontiers in cell and developmental biology2022

Plasmalogen Loss in Sepsis and SARS-CoV-2 Infection.

Daniel P Pike, Reagan M McGuffee, Elizabeth Geerling, Carolyn J Albert, Daniel F Hoft, Michael G S Shashaty, Nuala J Meyer, Amelia K Pinto, David A Ford

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Daniel P PikeEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Reagan M McGuffeeEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Elizabeth GeerlingDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Carolyn J AlbertEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Daniel F HoftDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Michael G S ShashatyPulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Nuala J MeyerPulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States.
Amelia K PintoDepartment of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, United States.
David A FordEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO, United States.
Saint Louis University · USUniversity of Pennsylvania · US

Funding

Investigating Individual Susceptibility and Host Response in Acute Respiratory Distress SyndromeR35HL161196 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Nuala Jennings Meyer · 2022 to 2026
$4.8M
Chlorinated lipids in sepsisR01GM115553 · NIGMS · SAINT LOUIS UNIVERSITY · PI FORD, DAVID A., MCHOWAT, JANE · 2015 to 2021
$3.0M
Targeting Angiopoietin-2 in ARDSR01HL137006 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MEYER, NUALA JENNINGS · 2017 to 2021
$2.5M
Reconsidering the IL-1 axis in sepsis-associated ARDSR01HL137915 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MEYER, NUALA JENNINGS · 2017 to 2020
$2.1M
Liquid Chromatography/ESI-MS Triple Quadrupole SystemS10OD025246 · OD · SAINT LOUIS UNIVERSITY · PI FORD, DAVID A. · 2019 to 2019
$244k
NHLBI NIH HHS R01 HL137006NHLBI NIH HHS R01 HL137915NHLBI NIH HHS R35 HL161196NIGMS NIH HHS R01 GM115553NIH HHS S10 OD025246
6 · The paper itself

Abstract

Plasmalogens are plasma-borne antioxidant phospholipid species that provide protection as cellular lipid components during cellular oxidative stress. In this study we investigated plasma plasmalogen levels in human sepsis as well as in rodent models of infection. In humans, levels of multiple plasmenylethanolamine molecular species were decreased in septic patient plasma compared to control subject plasma as well as an age-aligned control subject cohort. Additionally, lysoplasmenylcholine levels were significantly decreased in septic patients compared to the control cohorts. In contrast, plasma diacyl phosphatidylethanolamine and phosphatidylcholine levels were elevated in septic patients. Lipid changes were also determined in rats subjected to cecal slurry sepsis. Plasma plasmenylcholine, plasmenylethanolamine, and lysoplasmenylcholine levels were decreased while diacyl phosphatidylethanolamine levels were increased in septic rats compared to control treated rats. Kidney levels of lysoplasmenylcholine as well as plasmenylethanolamine molecular species were decreased in septic rats. Interestingly, liver plasmenylcholine and plasmenylethanolamine levels were increased in septic rats. Since COVID-19 is associated with sepsis-like acute respiratory distress syndrome and oxidative stress, plasmalogen levels were also determined in a mouse model of COVID-19 (intranasal inoculation of K18 mice with SARS-CoV-2). 3 days following infection, lung infection was confirmed as well as cytokine expression in the lung. Multiple molecular species of lung plasmenylcholine and plasmenylethanolamine were decreased in infected mice. In contrast, the predominant lung phospholipid, dipalmitoyl phosphatidylcholine, was not decreased following SARS-CoV-2 infection. Additionally total plasmenylcholine levels were decreased in the plasma of SARS-CoV-2 infected mice. Collectively, these data demonstrate the loss of plasmalogens during both sepsis and SARS-CoV-2 infection. This study also indicates plasma plasmalogens should be considered in future studies as biomarkers of infection and as prognostic indicators for sepsis and COVID-19 outcomes.

Indexed as

infectioninflammationlipidomicsplasmalogenSARS-CoV-2sepsis

Identifiers

PMID35784479
PMCPMC9242022
OpenAlexW4281774496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.